Alpha-Tocopherol Acetate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Alpha-Tocopherol Acetate
- alpha-Tocopherol acetate: From an Unspecified Original Indication to Drug-Induced Osteoporosis
alpha-Tocopherol acetate: From an Unspecified Original Indication to Drug-Induced Osteoporosis
One-Sentence Summary
Alpha-tocopherol acetate is a form of vitamin E, and it is marketed in Singapore as a component of an injectable multivitamin product (CERNEVIT). The licence record compiled for this report does not state an approved indication. The TxGNN model predicts it may be effective for drug-induced osteoporosis, but there are 0 clinical trials and 0 publications supporting this specific prediction, so it rests on model prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the licence record |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, alpha-tocopherol acetate is the ester form of vitamin E, a lipid-soluble antioxidant. It is supplied in Singapore as part of an injectable multivitamin preparation.
A plausible but unverified link is that vitamin E's antioxidant activity could reduce oxidative-stress-mediated bone loss, which may be relevant to drug-induced osteoporosis. This is speculative, and no trials or literature in the data compiled for this report support it.
Other predictions in the same dataset: The model also ranks several cataract subtypes (diabetic, immature, mature, tetanic, craniostenosis, type 2 diabetes-associated, nuclear senile and cortical cataract) and diabetic retinopathy highly. The strongest supporting data are for diabetic retinopathy, where two preclinical rat studies suggest antioxidants, including vitamin E, act on oxidative-stress pathways in the diabetic retina (Evidence Level L4, "Research Question"). Diabetic cataract has one indirect animal study (L4). All other predictions are model-only (L5).
Clinical Trial Evidence
Currently no related clinical trials registered for drug-induced osteoporosis. No clinical trials were found for the other predicted indications either.
Literature Evidence
Currently no related literature available for drug-induced osteoporosis.
For reference, the literature compiled for the next-ranked predictions (all preclinical):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11222918 | 2001 | Preclinical (diabetic rats) | Neurochemistry International | Examined the effect of antioxidant supplementation on diabetes-induced changes in retinal glutamate and its relationship with oxidative stress and nitric oxide (diabetic retinopathy) |
| 14703729 | 2003 | Preclinical (diabetic rats) | Free Radical Research | Diabetes activated the redox-sensitive transcription factor NF-kappaB in the retina, and antioxidant supplementation inhibited this (diabetic retinopathy) |
| 12770645 | 2003 | Animal study (rats) | Journal of Nutritional Biochemistry | Vitamin E (dl-alpha-tocopherol acetate) supplementation and carbon tetrachloride-induced oxidative stress; an indirect model, not a diabetic cataract model |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11975P | CERNEVIT FOR INJECTION | Injection, powder, for solution | Not stated in the licence record |
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found for this drug, and no disease-level contraindications were identified in the knowledge graph.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for drug-induced osteoporosis has a high model score but no supporting trials or literature (L5). The antioxidant rationale is plausible but unverified. Package insert safety information is also not yet available.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website, which are required before any safety screening
- Mechanism of action data (for example, from DrugBank)
- A literature search on vitamin E and bone loss in drug-induced osteoporosis, such as glucocorticoid-induced cases
- Consideration of whether diabetic retinopathy, which has preclinical support, is a better lead indication to pursue as a research question
- Confirmation of whether the injectable multivitamin route and dose are suitable for any new indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.